Contact Form

Please fill in the form below, or if you prefer, contact us directly:

Genetic Engineering & Biotechnology News
140 Huguenot Street, 3rd Floor
New Rochelle, NY 10801-5215 USA
Phone (914) 740-2100
Fax (914) 740-2201 or toll free 1-800-7999-GEN

* Required

CAREER CENTER

visit the Career Center

WEBINARS

GEN Webinars: Transformative Technologies for Peptide Bioanalysis
Date: Thursday, December 10, 2009
LC/MS has established itself as the method of choice for analysis of therapeutic peptides because it ...learn more.

Dec 15 2009
GEN Webinars: Shifting Cell-Line Development into High Gear
sponsored by Cyntellect

view all webinars

GEN and Scintellix bring you the Cryptogram Challenge: ELISA REDUX!

PODCASTS

INTERVIEW: (BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.) ...MORE

MOST POPULAR

News

Most Viewed	Most Emailed	Top Searches
Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
Qiagen Snags SABiosciences for $90M to Boost Diagnostic Capabilities
FDA Clears CSL's Seasonal and Swine Flu Vaccines for Pediatric Populations
Novartis’ Swine Flu Vaccine Effective at Half the Current Antigen Dose
Tethys Secures $25M to Expand Reach of Type 2 Diabetes Test
GSK Signs On Astex in Broad Partnership for About $33M Up Front

Most Viewed	Most Emailed	Top Searches
Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
Life Technologies Acquires BioTrove to Bolster PCR Business
Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
Novartis’ Swine Flu Vaccine Effective at Half the Current Antigen Dose
Qiagen Snags SABiosciences for $90M to Boost Diagnostic Capabilities
Altair Raises $17M to Progress Phase II Trials with Antisense Asthma Treatment

Most Viewed	Most Emailed	Top Searches
Novartis’ Swine Flu Vaccine Effective at Half the Current Antigen Dose
Novartis to Buy 85% of Chinese Vaccines Company for $125M
Calbiotech Wins Phase I SBIR Contract to Develop Blood-Based Dengue Fever Diagnostic
Biota Acquires Assets from Prolysis and MaxThera for Roughly $11.5M
Fate Therapeutics Scores $30M to Advance Its Adult Stem Cell Technology
FDA Clears CSL's Seasonal and Swine Flu Vaccines for Pediatric Populations

Articles

Most Viewed	Most Emailed	Top Searches
Flow Cytometry's Expanding Niche
Search Intensifies for Diabetes Drugs
Next-Generation RNA Interference
Cellular-Signaling Pathway Signatures
Searching for Appropriate Cancer Biomarkers
Cracking Down on Misinformation

Most Viewed	Most Emailed	Top Searches
Flow Cytometry's Expanding Niche
Certainty Not Required for Inventorship
Transfection Market Clamors for Silver Bullet
Search Intensifies for Diabetes Drugs
Single-Use Systems Make Headway with Skeptics
Cracking Down on Misinformation

Most Viewed	Most Emailed	Top Searches
Searching for Appropriate Cancer Biomarkers
Funding Embryonic Stem Cell Research
Cells That Get No Respect
Optimizing CHO Cell Culture Conditions
Human Genome-Wide Association Studies
Lyophilization: Growing with Biotechnology

Blogs

Most Viewed	Most Emailed	Top Searches
Unclog the Innovation Bottleneck at our Nation’s Universities
Financial Bailout for the Little Guys in Research
Genetically Modified Foods Debate
BIO-Europe 2009 Day 3
BIO-Europe 2009 Day 2
Nanotechnologists Create Artificial Pore

Most Viewed	Most Emailed	Top Searches
Unclog the Innovation Bottleneck at our Nation’s Universities
(Bio) Banking in Luxembourg

Most Viewed	Most Emailed	Top Searches
Genetically Modified Foods Debate
Genetically Modified Foods - The Benefits
H1N1 Influenza vaccine manufacturers ramp up for October 15
Dr. James Watson Controversy
Unclog the Innovation Bottleneck at our Nation’s Universities
Financial Bailout for the Little Guys in Research

Name:	*
Position:
Institution/affiliation:
Department:
Address:	*
Address 2:
City/town:	*
Country:	*
State/province:	*
ZIP/postal code:
E-mail:	*
Confirm e-mail:	*
Phone:	--ext. * *
Fax:	--
Question regarding:	*
Question:*

CURRENT ISSUE

SUBSCRIBE

AD LINK

Contact Form

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR

News

Articles

Blogs

CURRENT ISSUE

SUBSCRIBE

AD LINK

Contact Form

CAREER CENTER

Visit the GEN Career Center

WEBINARS

PODCASTS

MOST POPULAR

News

Articles

Blogs